Patents by Inventor Iris Klewinghaus

Iris Klewinghaus has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6730483
    Abstract: A phagemid has been constructed that expresses an antibody fused to coliphage pIII protein. The phagemid is suitable for selecting specific antibodies from large gene libraries with small quantities of antigen. The antibody-pIII gene can be strongly repressed, so that it allows antibody libraries to be amplified without the danger of deletion mutants predominating. After induction, large quantities of the fusion protein may be expressed.
    Type: Grant
    Filed: April 8, 2002
    Date of Patent: May 4, 2004
    Assignee: Deutsches Krebsforschungszentrum Stiftung des offentlichen Rechts
    Inventors: Frank Breitling, Melvyn Little, Stefan Dübel, Michael Braunagel, Iris Klewinghaus
  • Publication number: 20020160463
    Abstract: A phagemid has been constructed that expresses an antibody fused to coliphage pIII protein. The phagemid is suitable for selecting specific antibodies from large gene libraries with small quantities of antigen. The antibody-pIII gene can be strongly repressed, so that it allows antibody libraries to be amplified without the danger of deletion mutants predominating. After induction, large quantities of the fusion protein may be expressed.
    Type: Application
    Filed: April 8, 2002
    Publication date: October 31, 2002
    Applicant: Deutsches Krebsforschungszentrum Stiftung des offentlichen Rechts
    Inventors: Frank Breitling, Melvyn Little, Stefan Dubel, Michael Braunagel, Iris Klewinghaus
  • Patent number: 6387627
    Abstract: A phagemid has been constructed that expresses an antibody fused to coliphage pIII protein. The phagemid is suitable for selecting specific antibodies from large gene libraries with small quantities of antigen. The antibody-pIII gene can be strongly repressed, so that it allows antibody libraries to be amplified without the danger of deletion mutants predominating. After induction, large quantities of the fusion protein may be expressed.
    Type: Grant
    Filed: August 25, 2000
    Date of Patent: May 14, 2002
    Assignee: Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts
    Inventors: Frank Breitling, Melvyn Little, Stefan Dübel, Michael Braunagel, Iris Klewinghaus
  • Patent number: 6319690
    Abstract: The invention relates to the preparation and use of gene banks of human antibodies (Ab). Starting from a mixture of human B-lymphocytes, their mRNA is translated into the cDNA using oligo-dT primers. Subsequently, an amplification of the Ab-specific cDNA by means of polymerase chain reaction (PCR) takes place using suitable oligonucleotide primer sequences. Expression of this amplified Ab-specific cDNA in a bacterial expression vector, e.g. the vector pFMT described below, in E. coli thus makes available a human-antibody library with a comprehensive repertoire for screening selected antigens in vitro.
    Type: Grant
    Filed: May 6, 1993
    Date of Patent: November 20, 2001
    Assignee: Dade Behring Marburg GmbH
    Inventors: Melvyn Little, Frank Berthold Breitling, Thomas Seehaus, Stefan Dübel, Iris Klewinghaus
  • Patent number: 6127132
    Abstract: A phagemid has been constructed that expresses an antibody fused to coliphage pIII protein. The phagemid is suitable for selecting specific antibodies from large gene libraries with small quantities of antigen. The antibody-pIII gene can be strongly repressed, so that it allows antibody libraries to be amplified without the danger of deletion mutants predominating. After induction, large quantities of the fusion protein may be expressed.
    Type: Grant
    Filed: October 7, 1999
    Date of Patent: October 3, 2000
    Assignee: Deutsches Krebsforschungszentrum Stiftung des offentlichen Rechts
    Inventors: Frank Breitling, Melvyn Little, Stefan Dubel, Michael Braunagel, Iris Klewinghaus
  • Patent number: 5985588
    Abstract: A phagemid has been constructed that expresses an antibody fused to coliphage pIII protein. The phagemid is suitable for selecting specific antibodies from large gene libraries with small quantities of antigen. The antibody-pIII gene can be strongly repressed, so that it allows antibody libraries to be amplified without the danger of deletion mutants predominating. After induction, large quantities of the fusion protein may be expressed.
    Type: Grant
    Filed: August 17, 1998
    Date of Patent: November 16, 1999
    Assignee: Deutsches Krebsforschungszentrum Stiftung des offentlichen Rechts
    Inventors: Frank Breitling, Melvyn Little, Stefan Dubel, Michael Braunagel, Iris Klewinghaus
  • Patent number: 5849500
    Abstract: A phagemid has been constructed that expresses an antibody fused to coliphage pIII protein. The phagemid is suitable for selecting specific antibodies from large gene libraries with small quantities of antigen. The antibody-pIII gene can be strongly repressed, so that it allows antibody libraries to be amplified without the danger of deletion mutants predominating. After induction, large quantities of the fusion protein may be expressed.
    Type: Grant
    Filed: May 10, 1993
    Date of Patent: December 15, 1998
    Assignee: Deutsches Krebsforschungszentrum Stiftung des Offentlichen Rechts
    Inventors: Frank Breitling, Melvyn Little, Stefan Dubel, Michael Braunagel, Iris Klewinghaus
  • Patent number: 5840479
    Abstract: The invention relates to the preparation and use of gene banks of synthetic human antibodies (huAb) or parts of antibodies which contain the antigen-binding domain. Starting from a huAb framework in a suitable vector, the hypervariable regions of the antibody cDNA are formed by almost "randomly" combined oligonucleotides. Relatively conserved amino acids in the hypervariable regions have here been taken account of in the choice of appropriate nucleotides during the oligonucleotide synthesis and the ratio of the nucleotides used is likewise chosen such that a nonsense codon is to be expected at most in every 89th position. Expression of this synthetic huAb cDNA in microbial expression systems, e.g. in E. coli in the vector pFMT which is described below, thus makes a synthetic huAb library with a comprehensive repertoire for screening using selected antigens available in vitro.
    Type: Grant
    Filed: December 2, 1994
    Date of Patent: November 24, 1998
    Assignee: Behring Diagnostics GmbH
    Inventors: Melvyn Little, Frank Berthold Breitling, Thomas Seehaus, Stefan Dubel, Iris Klewinghaus